IGC Pharma, Inc. (IGC)
0.192
-0.05
(-19.56%)
USD |
NYAM |
Oct 29, 11:41
IGC Pharma Enterprise Value : 25.18M for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 25.18M |
| October 27, 2026 | 26.12M |
| October 26, 2026 | 26.32M |
| October 23, 2026 | 25.92M |
| October 22, 2026 | 26.10M |
| October 21, 2026 | 25.56M |
| October 20, 2026 | 25.82M |
| October 19, 2026 | 25.51M |
| October 16, 2026 | 25.92M |
| October 15, 2026 | 26.75M |
| October 14, 2026 | 26.53M |
| October 13, 2026 | 27.87M |
| October 12, 2026 | 29.00M |
| October 09, 2026 | 29.39M |
| October 08, 2026 | 29.91M |
| October 07, 2026 | 29.40M |
| October 06, 2026 | 29.40M |
| October 05, 2026 | 29.61M |
| October 02, 2026 | 28.88M |
| October 01, 2026 | 28.38M |
| September 30, 2026 | 28.27M |
| September 29, 2026 | 28.12M |
| September 28, 2026 | 28.79M |
| September 25, 2026 | 29.65M |
| September 24, 2026 | 29.52M |
| Date | Value |
|---|---|
| September 23, 2026 | 30.03M |
| September 22, 2026 | 29.71M |
| September 21, 2026 | 28.79M |
| September 18, 2026 | 29.92M |
| September 17, 2026 | 28.01M |
| September 16, 2026 | 28.59M |
| September 15, 2026 | 28.06M |
| September 14, 2026 | 28.94M |
| September 11, 2026 | 29.26M |
| September 10, 2026 | 29.71M |
| September 09, 2026 | 29.56M |
| September 08, 2026 | 30.42M |
| September 04, 2026 | 31.25M |
| September 03, 2026 | 31.30M |
| September 02, 2026 | 31.03M |
| September 01, 2026 | 31.12M |
| August 31, 2026 | 31.37M |
| August 28, 2026 | 32.48M |
| August 27, 2026 | 34.93M |
| August 26, 2026 | 32.24M |
| August 25, 2026 | 31.92M |
| August 24, 2026 | 31.51M |
| August 21, 2026 | 32.27M |
| August 20, 2026 | 29.12M |
| August 19, 2026 | 29.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 12.75M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| Arvinas, Inc. | -63.42M |
| Fulcrum Therapeutics, Inc. | -27.49M |
| Definium Therapeutics, Inc. | 4.072B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.936M |
| Revenue (Quarterly) | 0.265M |
| Total Expenses (Quarterly) | 3.201M |
| EPS Diluted (Quarterly) | -0.0293 |
| Gross Profit Margin (Quarterly) | 2.64% |
| Profit Margin (Quarterly) | -1.11K% |
| Earnings Yield | -42.50% |
| Normalized Earnings Yield | -42.50 |